Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COAST phase 3 trial of OPT-302 plus aflibercept versus aflibercept alone in neovascular age-related macular degeneration
MOH_2021-08-24_010215Phase 3Not yet recruiting
- Sponsor
- Opthea Limited
- Start
- Jul 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sozinibercept and aflibercept in exudative macular degeneration (3 arms), sponsored by Opthea Limited. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
soziniberceptaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2021-08-24_010215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-24_010215.